The pharmacokinetic profile of oral zidovudine entrapped in a 50:50 polyact
ide-coglycolide matrix (nanospheres) was compared to those of standard oral
and parenteral zidovudine formulations in rabbits. The bioavailability of
zidovudine nanospheres at 50 mg/kg of body weight was 76%, and this dose ac
hieved prolonged exposure to zidovudine compared to standard formulations w
ithout an increase in the drug's peak concentration.